[ad_1]
Aaron Ondry joins us as Chief Financial Officer, bringing extensive leadership experience in financial management, strategic planning, commercial finance and capital allocation.
Key appointments will be added within the existing corporate leadership team, expanding capabilities and expertise from early discovery to commercialization.
Cranberry, NJ, March 26, 2024–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated late-stage biotechnology company, is developing gene therapy solutions for rare diseases with high unmet needs. We are driving sustainable pipelines and today announced the appointment of Aaron Ondry. , will aim to further evolve the corporate leadership team through his appointment as Chief Financial Officer and key appointments with existing team members. These leadership announcements strengthen and expand Rocket’s readiness for a planned transition to the commercial stage and continued development of the pipeline.
Aaron Ondry He joins Rocket as Chief Financial Officer with more than 20 years of experience in financial management, strategic planning, commercial finance, capital allocation, and M&A, having held multiple financial leadership positions across the pharmaceutical and biotech industries. Mr. Ondry most recently served as CFO of Mirati Therapeutics through the launch of KRAZATI® and the company’s acquisition by Bristol-Myers Squibb in January 2024. He brings valuable expertise to support Rocket’s commercial transition and growth trajectory, particularly strong financial acumen and outstanding operational management. ability. Prior to joining Mirati, Mr. Ondry also held senior management positions at Arena Pharmaceuticals, Alexion Pharmaceuticals and Regeneron Pharmaceuticals.
Key appointments within Rocket’s existing corporate leadership team include:
-
Kinnari Patel, PharmD, MBA; Appointed president, director of research and development, and chief operating officer. Dr. Patel will focus on research and development, overseeing research through late-stage development and manufacturing. Additionally, she will continue to maintain her position as COO and drive company operations aimed at advancing the company’s key strategic priorities.
-
Dr. Jonathan Schwartz, Appointed chief medical and gene therapy officer, his responsibilities span research and discovery and clinical development. Dr. Schwartz brings deep and experienced scientific and clinical thought leadership to continue developing and advancing Rocket’s current and future pipeline.
-
Mark White, MB.ChB, has been appointed General Manager, Commercial Affairs, leading Medical Affairs, Marketing, Commercial Operations, and Value & Access. Dr. White’s extensive drug development and franchise leadership experience, combined with the benefits of consolidating these capabilities under his leadership, will position Roquette for long-term success with highly complex therapies targeting rare diseases. can be accommodated.
-
Martin Wilson. J.D. has been appointed General Counsel and Chief Executive Officer and will lead legal affairs, compliance and corporate development. This evolution creates a newly integrated team aimed at advancing Rocket’s corporate strategy, led by Mr. Wilson’s strong legal and strategic acumen and experience.
“Today’s management announcements are particularly exciting as we expand our financial expertise with the addition of experienced financial leader Aaron Ondry as our Chief Financial Officer, as we move from a clinical organization to a commercial-stage genetics company. This highlights Rocket’s readiness as we transform into a treatment company,” said Gaurav Shah, MD. , CEO of Rocket Pharma. “Leveraging the wealth of talent and experience in our team, we are optimally positioning Rocket to achieve operational and commercial excellence, and to help patients with rare cardiovascular and hematological diseases. We look forward to continuing our strong momentum as we advance key pipelines for the
About Rocket Pharmaceuticals Co., Ltd.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated late-stage company driving a sustainable pipeline of investigational gene therapies designed to correct the root causes of complex and rare diseases. is a biotechnology company. Rocket’s innovative multi-platform approach allows us to design the best gene therapy for each indication, unlocking the potential to help people living with devastating rare diseases experience long, fulfilling lives. We can create some transformative options.
Rocket’s lentiviral (LV) vector-based gene therapy targets blood disorders, including Fanconi anemia, leukocyte adhesion deficiency I (LAD-I), a difficult-to-treat genetic disease that causes bone marrow failure and potentially cancer. The program consists of the latter half of the program. Pyruvate kinase deficiency (PKD), a severe childhood genetic disease that causes recurrent, life-threatening infections and is often fatal, is caused by a single gene that causes increased red blood cell destruction and mild to life-threatening anemia. Sexual red blood cell disease.
Our adeno-associated virus (AAV)-based cardiovascular portfolio includes a late-stage program in Danon’s disease, a severe heart failure condition that causes the heart to thicken, and an early program in clinical trials for PKP2 arrhythmogenic cardiomyopathy (ACM). It contains. , a preclinical program targeting BAG3-related dilated cardiomyopathy (DCM), a life-threatening heart failure disease that causes ventricular arrhythmias and sudden cardiac death, and heart failure disease that causes ventricular enlargement.
For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn, YouTube, and X.
Rocket’s Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding Rocket’s future expectations, plans and prospects that involve risks and uncertainties and if they do not materialize or prove to be inaccurate. , contains assumptions that our results may differ materially from those expressed or implied by the press release. Such a positive statement. The Company makes such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than historical facts contained in this release are forward-looking statements. These forward-looking statements include: “believe,” “expect,” “anticipate,” “intend,” “plan,” “will,” “estimate,” “seek,” ” “’would,’ ‘may,’ ‘suggest,’ or similar terms, variations of such terms, or negative forms of such terms. These forward-looking statements include: Including, but not limited to, statements regarding expectations. drug deficiency disease (PKD), Danon’s disease (DD) and other diseases; anticipated timing and data readouts of Roquette’s ongoing and planned clinical trials; anticipated regulatory responses and planned filings of Roquette; Key collaborations and vendors regarding the product candidate, including the timing and results of the development, the safety, efficacy, and timing of Rocket’s DD program, planned pivotal clinical trials, and related preclinical studies and clinical trials. Rocket’s ability to establish relationships, develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates and additional indications compatible with its gene therapy technology; Rocket’s ability to expand the pipeline to target. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee such results. Actual results may differ from these forward-looking statements as a result of a variety of important factors, including, but not limited to, Rocket’s dependence on third parties to develop, manufacture, market, sell and distribute its product candidates, and the outcome of litigation. The results may differ materially from those expressed in the description. unanticipated expenses, the activities of Rocket’s competitors (including decisions regarding the timing, pricing, and discounts of competing products), the development, acquisition, promotion, sufficient patient enrollment, and clinical development of Rocket’s product candidates; Rocket’s ability to successfully complete research, acquire additional businesses, form strategic alliances or create joint ventures and realize the benefits of such acquisitions, alliances or joint ventures, product candidates; Rocket’s ability to obtain and enforce patents to protect, and successfully defend. Unanticipated Third Party Infringement Claims, and the Risks Thereof, are discussed in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 27, 2024. It is further explained in the section entitled “Risk Factors”. and subsequent filings with the SEC, including quarterly reports on Form 10-Q. Therefore, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date they are made, and Rocket undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. not.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240326360522/ja/
contact address
media
Kevin Giordano
media@rocketpharma.com
Investor
brooks larmer
investor@rocketpharma.com
[ad_2]
Source link
